... and get this ARYC
announced that they appointed DOCRO, Inc. of
Seymour, Connecticut, to assist in obtaining a
'Fast Track' FDA approval for OvaDx! This is HUGE
NEWS! DOCRO has steered nearly 100 In Vitro Diagnostic
(IVD) clinical trials through the Food and Drug
Administration in the past 12 years, along with 39
pre-market approval (PMA) and 46 510(k) applications.
DOCRO has an
unparalleled 99% success rate with the FDA!
So you think DNDN was a big
winner that you missed out on? In our opinion, ARYC
is close to getting their FDA approval and once they
do we believe long-term that ARYC could become even
BIGGER than DNDN! ARYC is only 80 cents as we speak!
Arrayit's microarray test, which
detects both early and late stage ovarian cancer,
leverages the company's patented microarray platform
and distinguished 13-year track record as a
microarray technology leader! If you didn't know,
ARYC has been around for 17 years
but just did their merger a year ago so nobody even
knows it exists!
What does this tell you! This is a NO
BRAINER! I don't think ARYC will be
under a buck for much longer!
On top of all of this, ARYC
is also working on other Pre-Symptomatic tests for
other diseases such as Parkinson, Prostate and
Breast Cancer! Think about the upside potential
here!!!
There is so much more exciting info
to go over with you on ARYC so
please look out for our alerts this weekend and we
apologize for sending more than usual but this is a
unique discovery!
Just a hint... ARYC
is the market leader in the Microarray Tech. having
the #1 Position in the world!
Don't believe me? Do some research on ARYC's
President Mark Schena! Here are a couple of links to
get you started-
Right now, ARYC has
a market cap of only about $18 MM at the current PPS
of $0.80. Now compare ARYC's 650
products and 3,500 installed Platforms sold to over
10,000 pharma Co./Labs in 50 countries along with
its revolutionary Ovarian Cancer Pre- Diagnostic
test heading for FDA Approval (not to mention all of
the other diseases the company is working on) to its
competitors valuations.
The industry has been historically
dominated by Affymetrix (Nasdaq: AFFX)
which achieved strong market penetration by being
the first public company to commercialize and
promote microarray applications. AFFX
has made a run from as low as about $2 to as high as
$10 in the past 2 years for a gain of
400%. A more
recent entry to the market, Illumina (Nasdaq:
ILMN), has taken significant market share
from Affymetrix. AFFX has a market
cap of about $472 MM at $6.95 with 13% revenue
growth and ILMN has a market cap of
over $5 BILLION at $41.83 with 12% revenue growth!
However, both competitors face mid to
long term scientific and technological challenges
because they are limited by what they can deposit
onto a microarray--DNA. ARYC's
PATENTED printing technology can deposit any
kind of molecule into a microarray, including DNA,
proteins, antibodies, diagnostic elements and other
compounds!
These next generation microarrays
represent the LARGEST growth opportunity in the
industry!!! ARYC has a long-term
advantage in its unique line of personal and high
throughput microarray printers, highest sensitivity
microarray scanners, top quality consumables,
patented diagnostic methods, collaborative corporate
culture, AND competitive pricing!
In my opinion, the revenue growth
potential for ARYC is significantly
higher than both of these competitors and there is
no doubt that ARYC could become
a potential BUYOUT TARGET!
You want to see what kind of upside
potential we could see in the short term for these
type of FDA plays? Take a look at VRML!
VRML after getting FDA approval in
September of 2009 ran from $0.10 to a high
of $34 for a whopping gain of
33,900%!!!
Is that insane or what!
and your not going to believe
this... guess what VRML got FDA approval for that
sent them through the roof this much? . . .
That's right
it was an Ovarian Cancer test just like ARYC!!!!!!
But get this, VRML's Ovarian Test
is a test for Ovarian cancer in Stage 3 while
ARYC's Ovarian Cancer test is a
PRE-SYMPTOMATIC
test that finds the cancer before you even go
through stage 1 of side effects! Every woman in the
world is going to want to take this test once
approved! To top it off with Obama's new healthcare
reform, every insurance and medicaide is going to
want to pay for this! Just think about this...
would you rather pay a few hundred dollars for a
test that would find the cancer before you even have
one symptom or hundreds of thousands of dollars in
treating the condition in a stage where death is
most likely!? FYI, VRML has a
market cap of over $100 Million with no revenue
where ARYC's market cap is under
$20 Million with revenue and a better Ovarian
Cancer Test!
Can you believe this! It just keeps
getting better and better doesn't it!
I told you this was a NO BRAINER!
A few others you could look into are
LIFE with almost a $10 Billion
market cap; 60% revenue growth, ISRG
with over a $14 Billion market cap; 40% revenue
growth, SQNM with a $385 Million
market cap and has a negative 20% sales decline.
As you can see investments in this
SECTOR ARE HOT RIGHT
NOW!
When I said ARYC is
a GROUND FLOOR OPPORTUNITY
with astronomical upside potential I meant it!
With only about a 4 MM float who
knows how high ARYC could go!
